This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Earnings Preview: Emergent Biosolutions (EBS) Q3 Earnings Expected to Decline
by Zacks Equity Research
Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Emergent (EBS) Inks COVID-19 Manufacturing Deal With Providence
by Zacks Equity Research
Emergent (EBS) is set to provide manufacturing services for doses of Providence Therapeutics' COVID-19 vaccine candidate as well as for its bulk drug substance.
New Strong Sell Stocks for August 2nd
by Zacks Equity Research
ATTO, BLDP, NTB, CCJ and EBS have been added to the Zacks Rank #5 (Strong Sell) List on August 2, 2021.
Emergent (EBS) Misses on Q2 Earnings, to Restart Bayview Unit
by Zacks Equity Research
Emergent's (EBS) second-quarter 2021 earnings miss estimates. Revenues also fail to meet expectations. Stock down.
Emergent Biosolutions (EBS) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -81.77% and -4.39%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Emergent Biosolutions (EBS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vaxart (VXRT) Enters an Agreement With Altesa for Antiviral
by Zacks Equity Research
Vaxart (VXRT) enters a licensing agreement with Altesa Biosciences, Inc., whereby the latter gets rights to develop, manufacture and commercialize vapendavir.
AstraZeneca (AZN) Gets Court Order to Supply COVID-19 Jabs in EU
by Zacks Equity Research
A court in Brussels orders AstraZeneca (AZN) to supply 80 million doses of its COVID-19 vaccine to Europe by Sep 27, 2021. The European Commission had requested for 300 million doses by end of September.
J&J (JNJ) Gets FDA Nod for 10M COVID Vaccines, Discards Many
by Zacks Equity Research
J&J (JNJ) gets authorization for two batches of COVID-19 vaccine doses manufactured at Baltimore facility but the FDA discards several others. Europe and Canada stop the rollout of some batches of the vaccine.
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
by Zacks Equity Research
Sector ETF report for SBIO
Emergent (EBS) Issues Plan to Resume Bayview Facility Operation
by Zacks Equity Research
Emergent (EBS) starts to make improvements at its Baview facility in order to meet FDA's standard and resume production of J&J's COVID-19 vaccine.
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
by Zacks Equity Research
Sector ETF report for SBIO
Emergent (EBS) Beats on Q1 Earnings, Cuts Contract Revenue View
by Zacks Equity Research
Emergent's (EBS) earnings in the first quarter of 2021 beat estimates while revenues miss the same. It lowers guidance for revenues from CDMO services. Stock down.
New Strong Sell Stocks for April 30th
by Zacks Equity Research
ARAY, EBS, FARM, SHLX, and TPB have been added to the Zacks Rank #5 (Strong Sell) List on April 30, 2021
Emergent Biosolutions (EBS) Q1 Earnings Top Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 57.73% and -6.95%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Emergent (EBS) This Earnings Season?
by Zacks Equity Research
On Emergent's (EBS) upcoming first-quarter earnings call, investors are likely to focus on the company's update related to re-start of production at its Bayview facility.
Moving Average Crossover Alert: Emergent BioSolutions (EBS)
by Zacks Equity Research
Emergent BioSolutions (EBS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Centene (CNC) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Centene's (CNC) first-quarter results are likely to reflect improving premiums and rise in membership, partly offset by escalating costs.
Emergent Biosolutions (EBS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Emergent Biosolutions (EBS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Emergent Biosolutions (EBS) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Emergent Biosolutions (EBS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
J&J (JNJ) Gets Usage Guidance for COVID-19 Vaccine in Europe
by Zacks Equity Research
J&J (JNJ) is set to resume shipments of its COVID-19 vaccine to European countries, following positive recommendation from EMA's Pharmacovigilance Risk Assessment Committee (PRAC).
Emergent (EBS) Bayview Unit Operation on Hold for FDA Probe
by Zacks Equity Research
Emergent (EBS) halts manufacturing at Bayview facility as the FDA initiates investigation of the error that led to manufacturing of faulty doses of J&J's COVID-19 vaccine.
Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Acadia (ACAD) and vaccine updates from quite a few companies like Emergent (EBS), among others.
Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Acadia (ACAD) and vaccine updates from quite a few companies like Emergent (EBS), among others.